A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p < 0.001) at 48 weeks at...
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing fo...
-Bayer and Vanderbilt University Medical Center (VUMC) announced that they have entered a strategic five-year collaboration agreement to advance innovati...
2026 is already shaping up to be a historic year for brain health as the healthcare industry confronts an urgent reality: cognitive impairment, Alzheimer...
ElpasBio Holdings ("ElpasBio"), a leading clinical-stage biotechnology company focused on regenerative medicine, announced that it has entered into a col...
Hongene Biotech announced the receipt of a grant from the Gates Foundation to develop high-quality, affordable, and patent-free cap analogs for use ...
Eli Lilly and Company (NYSE: LLY) and Ventyx Biosciences, Inc. (Nasdaq: VTYX), a San Diego-based clinical-stage biopharmaceutical company focused on...
PathAI, a global leader in AI-powered pathology, announced a strategic collaboration with University Hospital Zurich (USZ) to deploy AISight® Dx1, Pa...
Prokaryotics Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infectives, announced an agree...
Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India (SII), a Cyrus Poonawalla Grou...
Vanda Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has approved NEREUS™ (tradipitant), an oral neurokinin-1 (NK-...
NDA supported by results from a Phase II registration trial in China — — Second most common form of liver cancer after hepatocellular ...
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare ...
Diamyd Medical has reached alignment with the U.S. Food and Drug Administration (FDA) to accelerate the primary efficacy readout in its ongoing pivotal, ...
© 2026 Biopharma Boardroom. All Rights Reserved.
